LAPTM4B (lysosomal protein transmembrane 4 beta) is a newly identified cancer-associated gene. Both of its mRNA and the encoded LAPTM4B-35 protein are significantly upregulated with more than 70% frequency in a wide variety of cancers. The LAPTM4B-35 level in cancer is evidenced to be an independent prognostic factor and its upregulation promotes cell proliferation, migration and invasion, as well as tumorigenesis in nude mice. In contrary, knockdown of LAPTM4B-35 expression by RNA interference (RNAi) reverses all of the above malignant phenotypes. We herein reveal a new role of LAPTM4B-35 in promoting multidrug resistance of cancer cells. Upregulation of LAPTM4B-35 motivates multidrug resistance by enhancement of efflux from cancer cells of a variety of chemodrugs with variant structures and properties, including doxorubicin, paclitaxel and cisplatin through colocalization and interaction of LAPTM4B-35 with multidrug resistance (MDR) 1 (P-glycoprotein, P-gp), and also by activation of PI3K/AKT signaling pathway through interaction of PPRP motif contained in the N-terminus of LAPTM4B-35 with the p85a regulatory subunit of PI3K. The specific inhibitors of PI3K and knockdown of LAPTM4B-35 expression by RNAi eliminate the multidrug resistance effect motivated by upregulation of LAPTM4B-35. In conclusion, LAPTM4B-35 motivates multidrug resistance of cancer cells by promoting drug efflux through colocalization and interaction with P-gp, and anti-apoptosis by activating PI3K/AKT signaling. These findings provide a promising novel strategy for sensitizing chemical therapy of cancers and increasing the chemotherapeutic efficacy through knockdown LAPTM4B-35 expression by RNAi.
Introduction LAPTM4B (lysosomal protein transmembrane 4 beta) is a newly identified cancer-associated gene (NM_018407, Gene ID ¼ 55353) mapped to chromosome 8q22. 1, and encodes a 35 kDa tetratransmembrance glycoprotein . It has been reported that the LAPTM4B mRNA and the LAPTM4B-35 protein detected by western blot or immunohistochemistry are markedly upregulated in a wide variety of cancers, including HCC (more than 85%; Shao et al., 2003; Peng et al., 2005; Yang et al., 2009) , gallbladder carcinoma (76%; Zhou et al., 2006) , extra-hepatic cholangiocarcinoma (72%; Zhou et al., 2008) , lung cancer (88%), colon cancer (67%), uterus cancer (68%), breast cancer (50%; Kasper et al., 2005) and ovary cancer (69%; Yang et al., 2008) , as well as in adrenocorticotrophin-secreting adenomas and non-functioning pituitary adenomas (Morris et al., 2005) . Also, LAPTM4B-35 is highly expressed in a large number of cancer cell lines Liu et al., 2004) . It has been revealed that the levels of upregulated mRNA and LAPTM4B-35 protein are correlated significantly with pathological grades/differentiation of cancers and prognosis of patients with HCC, gallbladder carcinoma, extra-hepatic cholangiocarcinoma and ovary cancer Kasper et al., 2005; Zhou et al., 2006 Zhou et al., , 2008 Yang et al., 2008 Yang et al., , 2009 ). Overexpression of LAPTM4B-35 by transfection of LAPTM4B complementary DNA (cDNA) promotes deregulated cell proliferation, migration and invasion (Liu et al., 2009) , as well as tumorigenesis of mouse NIH3T3 cells (He et al., 2003) , growth and metastasis of human HCC xenografts in nude mice (Yang et al., 2010) . In contrary, knockdown of LAPTM4B-35 by RNA interference (RNAi) reverses all of the above malignant phenotypes (Yang et al., 2010) .
LAPTM4B-35 shows a 46% homology to a murine lysosomal tetra-transmembrane protein, mLAPTM4A (Hogue et al., 1996) at the amino acid level . It was reported that the mLAPTM4A functions in the transport of nucleosides and/or nucleoside derivatives between the cytosol and the lumen of an intracellular membrane-bound compartment and may confer multidrug resistance upon expression in Saccharomyces cerevisiae (Hogue et al., 1996 Cabrita et al., 1999) .
MDR is most commonly associated with human cancers and is the major obstacle to cancer chemotherapy (Ambudkar et al., 2003; Larsen et al., 2000) . This study aimed to explore whether LAPTM4B associates with MDR and to reveal the mechanism underlying this phenotype. LAPTM4B-overexpressing and -knocking down cells were applied to compare their potentials of drug resistance to doxorubicin, paclitaxel and cisplatin. The results demonstrated that overexpression of LAPTM4B-35 motivates multidrug resistance by enhancement of efflux from cancer cells of various cytotoxic drugs. The activation of PI3K/AKT signaling pathway, another important mechanism for MDR (Lee et al., 2004) , was also analyzed. The association of activation of PI3K/AKT signaling pathway with LAPTM4B-35 upregulation was revealed via increased p-AKT, and effects of PI3K inhibitors and dominant negative mutation of PI3K p85a. Interaction between LAPTM4B-35 and PI3K p85a was evidenced by coimmunoprecipitation (Co-IP) and GST-pulldown analyses. The binding sites were primarily identified by sitespecific mutations. In conclusion, LAPTM4B motivates multidrug resistance by enhancement of efflux from cancer cells of a variety of cytotoxic drugs and activation of PI3K/AKT signaling pathway.
Results

Expression of LAPTM4B-35 in wild-type and transfected HeLa cell lines
The expression of LAPTM4B-35 protein was analyzed by western blot using a purified polyclonal antibody directed a 10 amino acid-peptide in EC2 extracellular region of LAPTM4B-35. Figure 1a shows that the LAPTM4B-35 is upregulated in HeLa-AE cells, while it is markedly knocked down in HeLa-small hairpin RNA (shRNA) cells, when compared with their control HeLa-MOCK cells, respectively.
Increasing drug-resistance in HeLa cells by upregulation of LAPTM4B-35, but increasing sensitivity to chemotherapeutic drugs by knock down of LAPTM4B-35 expression To explore the effects of LAPTM4B-35 on drug sensitivity, we first examined the viability of HeLa cells, which express either high or low level of LAPTM4B-35 in a panel of three chemotherapeutic agents with variant structures, properties and known different mechanisms of action. As compared with the control HeLa-MOCK1 cells, the LAPTM4B-35-overexpressing HeLa-AE cells showed a higher viability curve, indicating significantly increased resistance to doxorubicin, paclitaxel and cisplatin ( Figure 1b) . In contrary, the HeLa-RNAi cells showed a lower viability curve, indicating significantly increased sensitivity to these three chemotherapeutic agents (Figure 1c) . Similar results were also obtained from PC-3 prostate cancer cell line (shown in Supplementary data). These results suggest that LAPTM4B-35 has a role in enhancing multidrug resistance.
Increasing Rhodamine-123 efflux in L02 cells by upregulation of LAPTM4B-35, but increasing Rhodamine-123 retain in HeLa cells by knock down of LAPTM4B-35 expression To compare Rhodamine-123 efflux in LAPTM4B-35-overexpressing and knockdown cells, L02 cell line, a cell line originated from human normal liver and expressed relatively low level of LAPTM4B-35, and HeLa cell line, a human cervical cancer cell line which expressed high level of LAPTM4B-35, were used, respectively. The results showed that the loaded fluorescence dye lost rapidly in L02-AE cells, but almost totally retained in L02-MOCK cells (Figure 2a ) during a period of 120 min, indicating that the Rhodamine-123 efflux is obviously promoted by LAPTM4B-35 overexpression. Adversely, the loaded fluorescence dye almost totally retained at the same level in HeLa-RNAi cells despite lost rapidly in HeLa-MOCK cells during a period of 120 min (Figure 2b ), indicating that the Rhodamine-123 efflux is prevented significantly by LAPTM4B-35 downregulation.
The time course of Rhodamine-123 efflux was also quantitatively detected by flow cytometry. The results (Figure 2e ) showed that the fluorescence retention curve was significantly higher in HeLa-RNAi cell population than that in the MOCK cell population, indicating that LAPTM4B-35-knockdown by RNAi can increase drug retention inside cancer cells.
Colocalization of LAPTM4B-35 and MDR1/P-glycoprotein (P-gp) The most common ATP-dependent membrane efflux transporters responsible for hydrophobic drug resistance are MDR1/P-gp and multidrug resistance-related protein (MRP) 1, which contain two ATP-binding cassettes in the cytoplasmic region (Ambudkar et al., 2003) . As LAPTM4B-35 does not contain ATP-binding cassette, it is unlikely that it functions as an efflux pump itself. To investigate whether the MDR effect motivated by LAPTM4B-35 upregulation is associated with the ATP-dependent membrane efflux transporter, Laser Scanning Confocal Microscopic analysis was applied with anti-LAPTM4B-35 antibody and anti-MDR1 or anti-MRP1 antibody. The results showed that LAPTM4B-35 is colocalized with MDR1/P-gp (Figure 2c ), but not MRP1 (Supplementary data), at plasma membrane and endomembrane organelles, suggesting these two proteins may directly interact or be co-transported inside cell.
Interaction of LAPTM4B-35 and MDR1/P-gp To further investigate the association of LAPTM4B-35 with MDR1/P-gp, co-immunoprecipitation was performed ( Figure 2d ). P-gp or MRP1 was immunoprecipitated with specific pAb, and western blots of immunoprecipitates were carried out using a pAb directed against LAPTM4B-35. LAPTM4B-35 was LAPTM4B motivates multidrug resistance L Li et al detected in immune complexes immunoprecipitated with P-gp antibody, but not MRP1 antibody. This experiment indicates that there is a physical interaction between P-gp and LAPTM4B-35.
The LAPTM4B-35-motivated MDR is eliminated by PI3K inhibitors PI3K/AKT signaling pathway, the most important mechanism for keeping cell survival, is also responsible for MDR and has been paid more and more attention (Tazzari et al., 2007) . PI3K/AKT signaling pathway is activated in HeLa cells (Barancı´k et al., 2006) . To explore the additional molecular mechanism of LAPTM4B-35 for MDR besides drug efflux, we detected the effects of PI3K inhibitors on LAPTM4B-35-associated MDR. The results showed that in the presence of LY294002 or Wortmannin, the specific inhibitor of PI3K, the enhanced MDR effect of HeLa-AE cells was eliminated ( Figure 3e and f compared with Figure 1b) , implicating the involvement of PI3K signaling in LAPTM4B-35-motivated MDR. The HeLa-MOCK1, HeLa-AE, HeLa-MOCK2 and HeLa-RNAi cells were exposed to increasing concentrations of doxorubicin, paclitaxel or cisplatin, respectively, for 48 h. Cell viabilities were determined by acid phosphatase assay as described in Materials and methods. Results were expressed as a mean±s. The interaction between LAPTM4B-35 and PI3K p85a regulatory subunit evidenced by GST-pulldown and Co-IP Structurally, the N-terminal tail in cytoplasmic region of LAPTM4B-35 contains a proline-rich motif PPRP, which is identical to that of the regulatory subunit p85a of PI3K . The proline-rich motif can be recognized and bound by SH3 domain of a variety of cytoplasmic signaling molecules, including PI3K regulatory subunit p85a. The interaction between LAPTM4B-35 and PI3K p85a was first evidenced by GST-pulldown in vitro. The GST-N1-99 and PPRPmutated (P12, 13, 15A) GST-N1-99 (PA) were applied to pull down the p85a-HA, which ectopically expressed in HeLa cells, and the pull down p85a-HA was identified by anti-HA antibody. The result ( Figure 3b ) showed that PI3K p85a-HA was detectable in GST-N1-99 pulldown. Although significantly reduced PI3K p85a-HA was not detected in a PPRP-mutated GST-N1-99 (PA) pulldown, suggesting that the LAPTM4B-35 interacts with p85a and this interaction contributes partially to the activation of PI3K. To demonstrate the interaction between LAPTM4B-35 and PI3K p85a in vivo, Co-IP analysis was performed in cells expressing wild-type LAPTM4B-35 and PPRP-mutated (P12, 13, 15A) LAPTM4B-35 (PA). As shown in Figure 3c , the interaction of LAPTM4B-35 and PI3K p85a existed in lysate from HeLa-AF cells, which expressed wild-type LAPTM4B-35, but reduced in lysate from PPRPmutated HeLa-AF (PA) cells. These results suggest that the PPRP motif in N-terminus of LAPTM4B-35 may be the binding site for PI3K p85a regulatory subunit.
To further demonstrate the interaction of LAPTM4B-35 and p85a regulatory subunit is associated with AKT phosphorylation/activation, we constructed a p85a-DN mutant, in which the PI3K p110 catalytic subunitbinding site of p85a was deleted. As such, the dominant negative p85a (DN-p85a) encoded by this mutant would be inactive for activating PI3K/AKT signaling. The HeLa cells were co-transfected with pcDNA-AE plasmids and p85a-DN plasmids. As shown in Figure 3d , the p-AKT 473 was reduced significantly in the co-transfectants of the dominant-negative p85a with Mock or AE plasmids when compared with the mono-transfectants with Mock or AE plasmids, indicating that the phosphorylation/activation of AKT 473 in either HeLa-Mock or HeLa-AE cells is dependent on PI3K activation through interaction between LAPTM4B-35 and p85a subunit.
Upregulation of LAPTM4B-35 inhibits chemodrugsinduced apoptosis, but knockdown of LAPTM4B-35 promotes apoptosis in HeLa-RNAi cells Failure of apoptosis is one of the mechanisms for MDR (Tsuruo et al., 2003) . Caspase 3 is the effector of caspase-dependent apoptosis. The caspase 3 activity can be measured by generation of cleaved poly (ADP-ribose) polymerase, the substrate of caspase 3. Our results (Figure 4c ) herein showed that in the presence of various chemotherapeutic drugs the cleaved poly (ADP-ribose) polymerase appeared in HeLa-Mock cells, but attenuated dramatically in HeLa-AE cells and recovered in HeLa-RNAi cells. These results indicate that upregulation of LAPTM4B-35 resists caspase-dependent apoptosis induced by various chemotherapeutic drugs, whereas downregulation of LAPTM4B-35 by RNAi can reverse the anti-apoptotic effect exerted by LAPTM4B-35-upregulaton. These results provide further evidence that upregulation of LAPTM4B-35 motivates MDR phenotype by evasion from drug-induced apoptosis via caspase-dependent pathway. 
LAPTM4B motivates multidrug resistance L Li et al
Discussion
Resistance to different chemotherapeutic drugs (multidrug resistance, MDR) is a major clinical obstacle in the treatment of cancers. Classical MDR is the consequence of overexpression of transporter proteins belonging to the ATP binding cassette (ABC) family, such as MDR1 (P-gp), MRPs and so on. The ABC superfamily includes several hundred different transport proteins, which share a structural similarity consisting of four domains: two transmembrane (T) domains and two cytosolic ATP-binding (A) domains. The drug efflux mediated by multidrug transporters dependents on the ATP-binding domains in transporter molecule and the energy released by ATP hydrolysis, and thus reducing intracellular drug concentrations to sublethal levels LAPTM4B motivates multidrug resistance L Li et al (Larsen et al., 2000; Gottesman, 2002) . Herein, we evidenced that LAPTM4B-35-upregulation, which occurs in a large number of solid cancers, can increase efflux of a variety of chemodrugs, including doxorubicin, paclitaxel and cisplatin, whereas LAPTM4B-35-knockdown by RNAi can decrease efflux and increase retention of drugs. Thus, LAPTM4B-35 is associated with MDR. However, there is no ATP binding sites in the molecular structure of LAPTM4B from bioinformatics analysis. Therefore, it might be less possibility that LAPTM4B-35 itself is a kind of multidrug transporter, despite LAPTM4A is thought to function as a transporter protein (Cabrita et al., 1999; Hogue et al., 1999) . Another mechanism for MDR involves in alterations in the apoptotic response associated with PI3K/AKT signaling. More and more experiments have recently revealed that the activation of PI3K/AKT signaling pathway can regulate or enhance multidrug resistance (Knuefermann et al., 2003; Abdul-Ghani et al., 2006; Tazzari et al., 2007) . This signaling pathway is activated in cervical cancer cells and the PI3K/AKT signaling inhibitor LY294002 can efficiently inhibits drug resistance and cell growth, and induced apoptosis in HeLa cells (Barancı´k et al., 2006) . In this study, we demonstrate via HeLa cell models that LAPTM4B-35-upregulation can strongly activate/phosphorylate AKT 473 by directly binding to PI3K p85 a subunit via the PPRP motif in the N-terminus of LAPTM4B-35 protein as evidenced by GST-pulldown and Co-IP analyses; these effects can be inhibited by PI3K inhibitors, LY294002 and Watmannin. Conversely, LAPTM4B-35-knockdown by RNAi can dramatically inhibit PI3K/AKT signaling as revealed in this study. In addition, chemotherapeutic drugs induce a series of cellular responses that impact on tumor cell proliferation and survival/apoptosis. In fact, several lines of evidence have suggested a direct correlation between alteration in survival pathways and chemoresistance (Tsuruo et al., 2003) . And some components of these pathways have been pointed as critical targets for cancer intervention. We also demonstrate herein that LAPTM4B-35-upregulation can inhibit drug-induced apoptosis by caspase-depentent pathway. Therefore, it is supposed that one of the mechanisms for LAPTM4B-35-upregulation motivated MDR is anti-apoptosis by activating PI3K/AKT signaling pathway.
It is generally thought that the overexpression of MDR1 (P-gp) encoded by mdr1 gene is a predominant cause of the acquisition of an MDR phenotype (Tsuruo et al., 2003) . The relationship between PI3K/AKT signaling and some transporter proteins, such as P-gp and MRP, have recently been revealed. For example, PI3K/AKT activity, analyzed by phosphatidylinositol trisphosphate production and p-AKT expression, is higher in the resistant cell lines than in the sensitive one; and inhibition with PI3K inhibitor, Wortmannin or LY294002, promotes apoptosis in the resistant cell lines and inhibits P-gp function and drug efflux (Garcı´a et al., 2008) . Our finding that LAPTM4B-35 overexpression motivates MDR, supports the concept that the ATPdependent drug efflux via P-gp is associated with antiapoptosis via activation of PI3K/AKT signaling. In addition, PI3K activation leads to mdr1 gene expression and subsequent chemoresistance in advanced prostate cancer cells (Lee et al., 2004) ; PI3K/AKT signaling controls MRP1 expression in human acute myelogenous leukemia blasts (Tazzari et al., 2007) . The P-gp expression was decreased by treatment with LY294002 in mouse L1210 leukemia cell line (Choi et al., 2007) and in human HeLa cell line, also the HeLa cell growth and induced-apoptosis were affected as well (Zhang et al., 2008) . However, the upregulation of P-gp in LAPTM4B-35 overexpressing HeLa and PC-3 cells was not found.
A number of multidrug-resistant cancer cells have been shown to have acquired an increased capacity to sequester weakly basic anticancer drugs in their acidic vesicles, including lysosomes and endosomes, relative to drug-sensitive counterparts. Lysosomal sequestration has a significant role in the emergence of MDR as lysosomes effectively sequester drugs away from their cellular targets (Duvvuri et al., 2005; Fu and Roufogalis, 2007) . The study on subcellular distribution of the basic drugs revealed that lysosome has the highest affinity for the basic drugs and responsible for biphasic uptake. The study on intracellular traffic of human P-gp revealed that a small fraction of the total P-gp-EGFP expressed was localized intracellularly and was present in early endosome and lysosome compartments (Fu and Roufogalis, 2007) . Membrane proteins may traffic to the cell plasma membrane via two distinct pathways. In the first, a constitutive/default pathway, membrane protein is incorporated into vesicles and directly moves from Interaction of p85a subunit with wild-type LAPTM4B-35 detected by GSTpulldown. GST-LAPTM4B-N1-99 and the PPRP-mutated GST-LAPTM4B-N1-99 (PA) were applied to pull down the p85a-HA, which ectopically expressed in HeLa cells. The pull down p85a-HA was identified by anti-HA antibody. (c) Interaction of p85a subunit with wild-type LAPTM4B-35 detected by Co-IP analysis. HeLa cells were co-transfected with pcDNA3-p85a-HA plasmids and pcDNA3-LAPTM4B-AF (the pcDNA3-LAPTM4B-AE with FLAG tag) or pcDNA3-LAPTM4B-AF (PA) plasmids. After serum starvation for 18 h, the transfected cells were incubated in the presence or absence of fetal calf serum (FCS) for 15 min, and then lysed for Co-IP analysis. The anti-FLAG antibody was used for immunoprecipitation. The anti-HA antibody was used for western blot. The p85a-HA can interact with wild-type LAPTM4B-35 in HeLa-AF cells, but not the mutated LAPTM4B-35 (PA) in HeLa-AF (PA) cells. (d) Inhibition of AKT phosphorylation in HeLa-AE cells by PI3K p85a dominant negative strategy. HeLa cells were co-transfected with pcDNA3-AE plasmids and pcDNA3-DNp85a plasmids, in which the PI3K p110-binding site of p85a was deleted, and thus DN-p85a is inactive for activating PI3K/AKT signaling. After 18 h starvation by serum-withdrawing from the cell culture medium, the cells were stimulated with 20% FCS for 15 min, then phophorylated AKT was measured by western blot. (e, f) Viability curves of LAPTM4B-35-upregulating HeLa-AE cells in the presence of LY294002 and Wortmannin, respectively.
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Golgi to the plasma membrane along the actin cytoskeleton. In the second pathway, traffic is through an intracellular endosomal system, with protein vesicles being transported to endosome compartments to form an intracellular pool, followed by further transport to the plasma membrane (Fu and Roufogalis, 2007) . For example, Kim et al. (1997) suggested that there was an intracellular pool of P-gp and that P-gp recycled between the plasma membrane and the intracellular pool, indicating a possible endocytosis pathway. Recently, the study on human breast cancer MCF-7 cells revealed that P-gp-EGFP traffic was shown to occur via early endosome transport to the plasma membrane. Subsequent movement of P-gp-EGFP away from the plasma membrane occurred by endocytosis to the early endosome and lysosome. However, the detailed mechanism of P-gp traffic has been little studied and is still unclear (Fu and Roufogalis, 2007) . As note, the LAPTM4B-35 protein possesses typical lysosome-targeting signals at both N-and C-terminal cytoplasmic LAPTM4B motivates multidrug resistance L Li et al tails, and also the endocytic adapter protein (AP) 1 binding site . It has been evidenced by Laser Scanning Confocal Microscopy in our lab that LAPTM4B-35 distributed at plasma membrane, endosomes and lysosomes (data not shown). In this study, we evidenced the colocalization of LAPTM4B-35 and P-gp on plasma membrane and endomembrane organelles, as well as the interaction of these two multi-transmembrane proteins. Thus, it is likely that LAPTM4B-35 may have important roles in driving endocytosis and trafficking of P-gp between plasma membrane and intracellular compartments. It is also possible that binding of LAPTM4B-35 to P-gp may contribute to its activation by alternating P-gp conformation. Further studies to reveal the effects of LAPTM4B-35 on trafficking or conformation of P-gp remain to be done. Taken together, LAPTM4B-35, that promotes cancer growth and metastasis, also has critical roles in MDR through increasing drug efflux by P-gp to reduce drug concentration in cytoplasm and activating PI3K/AKT signaling to escape from drug-induced apoptosis. Accordingly, LAPTM4B-35-knockdown by RNAi may provide a promising novel strategy to overcome MDR in cancer chemotherapy. It is possible that LAPTM4B-35 may be an important factor that involves in drugtransporter trafficking between plasma membrane and intracellular compartments.
Materials and methods
Cell lines and antibodies
Human cervical carcinoma HeLa cell line was from ATCC (Manassas, VA, USA) and kept in our laboratory. L02 cell line was originally from human normal liver established by Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China. The cell lines were cultured in RPMI 1640 medium supplemented with 10% serum. Antigen-peptide affinity chromatography purified rabbit anti-LAPTM4B-35 polyclone antibodies were produced in our lab by immunization of a KLH-conjugated synthetic peptide composed of 10 amino acid residues located at EC2 or N-terminus. Anti-Akt, anti-p-Akt and anti-poly (ADP-ribose) polymerase antibodies were purchased from Cell Signaling (Boston, MA, USA). Antib-actin polyclonal antibodies were from Zhong Shan Biotechnology Co., LTD (Beijing, China). Anti-P-gp mAb C219 was from Calbiochem (Merck KGaA, Darmstadt, Germany). Anti-P-gp pAb Mdr (H-241) was from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA).
Reagents Doxorubicin was purchased from Wanle Pharmaceutical (Shenzhen, China). Cisplatin was from XiLu Pharmaceutical (Shandong, China). Paclitaxel was kindly provided by Professor Wang Yongchao (Beijing Normal University, Beijing, China). LY294002, Wortmannin, Rhodamine-123 and acid phosphatase substrate were purchased from Sigma (St Louis, MO, USA).
Construction and transfection of the expressive plasmid
The expressive plasmids, pcDNA3-LAPTM4B-AE containing LAPTM4B ORF cDNA and the RNAi plasmid containing pSilencer-LAPTM4B-shRNA were constructed by Shao and Wei (Yang et al., 2010) in our lab, respectively. Transient transfection was conducted with pcDNA3, pcDNA3-LAPTM4B-AE (AE) or pSilencer, pSilencer-LAPTM4B-shRNA (shRNA) plasmids (Yang et al., 2010) . The resulted transfectants are designated as HeLa-MOCK1, HeLa-AE, HeLa-MOCK2 and HeLa-RNAi, respectively. After incubation for another 48 h, these cells were harvested for use in each experiment. L02 cells were infected by Ad-null and Ad-AE, an E1/E3-deleted replication-deficient adenovirus type 5 vector, which contains the whole ORF of LAPTM4B cDNA, and labeled as L02-MOCK and L02-AE, respectively.
Plasmid construction of PA mutant and p85a-DN mutant The pcDNA3-AE and pcDNA3-AF plasmids that contains a Flag-tag at the 3 0 end of pcDNA3-AE were used to construct the mutant plasmids.
For construction of pcDNA3-AF (PA) plasmids, LAPTM4B cDNA with P12, 13, 15A mutated (PA) DNA sequence was obtained by two-step PCR-amplification. First, two PCR-amplifications were carried out respectively using two pairs of primers Laptm4b-F-BamHI (5 0 -GGGATCCG CCACCATGACGTCACGGACTCGGGTC-3 0 ) and PA-1 (5 0 -GAGGGCGCGGGCCGCACTCGGCCATGTGACCCG AGT-3 0 ), PA-2 (5 0 -CACATGGCCGAGTGCGGCCCGCGC CCTCCCCGTCC-3 0 ) and Laptm4b-R-EcoRI (5 0 -CGGAATT CGGCAGACACGTAAGGTGGCGG-3 0 ). The two amplified fragments were mixed as the template of the second PCRamplification with Laptm4b-F-BamHI and Laptm4b-R-HindIII as primers. Then, the amplified fragment with P12, 13, 15A mutated sequence was cloned into pcDNA3-Flag plasmid and named as pcDNA3-AF (PA).
For construction of pGEX-KG-N1-99 (PA) plasmids, N1-99 (PA) DNA sequence of LAPTM4B cDNA was PCRamplified by using PA-F-BamHI (5 0 -CGGGATCCATGAC GTCACGGACTCGGGTC-3 0 ) and PA-R-HindIII (5 0 -CCCA AGCTTTCACGTCCAGGGCGCGACCATC-3 0 ) as forward and reverse primers, respectively, and pcDNA3-AF (PA) was used as the template. The amplified fragment was cloned into pGEX-KG plasmid and named as pGEX-KG-N1-99 (PA).
For construction of pcDNA3-p85a-HA and pcDNA3 p85a-DN-HA plasmids, p85a cDNA was PCR-amplified by using p85a-F-BamHI (5 0 -GGGATCCGCCACCATGAGTGCTGA GGGGTACCAG-3 0 ) and p85a-R-XbaI (5 0 -GCTCTAGAGC TTCCGCCGGGTCGCCTCTGCTGTG-3 0 ) as forward and reverse primers, respectively, and the L02 cell line cDNA was used as the template. The amplified fragment was cloned into pcDNA3-HA plasmid and named as pcDNA3-p85a-HA.
Another two PCR-amplifications were carried out using two pairs of primers p85a-F-BamHI and p85a-DN-1 (5 0 -ATTGCC TTCACGGCGGCTTTGGATTTCCTGGGATGTGCGGG T-3 0 ), p85a-DN-2 (5 0 -CAGGAAATCCAAAGCCGCCGTGA AGGCAATGAGAAAGAAATA-3 0 ) and p85a-R-XbaI. The two amplified fragments were mixed as the template of the last PCR with p85a-F-BamHI and p85a-R-XbaI as primers. Thus, the amplified fragment, in which p85a 479À513 , the interacting domain with p110a catalytic subunit of PI3K was deleted, and cloned into pcDNA3-HA plasmid and named as pcDNA3-p85a-DN-HA.
Determination of viability curves
Untransfected and transfected cells were exposed to various concentrations of chemotherapeutic agents and incubated for 48 h, the total viable cells were determined with the acid phosphatase assay (Yang et al., 1996) . Cell viability was Rhodamine-123 efflux assay Briefly, cells were seeded on culture plates and incubated with 1.5 mg/ml Rhodamine-123 for 20 min at 37 1C. Then the cells analyzed by laser-scanning microscope at an excitation wavelength of 488 nm. The photos were taken every 5 min.
In vitro GST-pulldown assay Approximately 20 mg of the GST-GST-N 1À99 -and GST-N 1À99 (PA)-fusion proteins was incubated with 40 ml of glutathione beads and 200 mg of HeLa cell lysates at 4 1C with gentle rocking for 2 h. Then the glutathione beads were washed four times with PBS containing NP-40 (0.5%), Triton X-100 (0.5%), NaF (20 mM) and protease inhibitors to remove nonspecifically bound proteins. Finally, the pulled down proteins were subjected to SDS-polyacrylamide gel electrophoresis and immunoblot analyses.
Co-IP assay
Lysates from various transfected HeLa cells or HCC tissue were pre-cleared with proteinA/G beads at 4 1C overnight before Co-IP. 500 mg of pre-cleared cell lysates were incubated with 1 mg of indicated antibody and 40 ml proteinA/G beads with gentle rocking at 4 1C overnight. After washing five times with washing buffer (PBS buffer containing protease inhibitors), the precipitated proteins were subjected to SDSpolyacrylamide gel electrophoresis and immunoblot analysis using relative antibodies. Each experiment was repeated at least three times.
Apoptosis assay
Cells were incubated with various chemotherapeutic reagents. Adherent and floating cells were both collected after 48 h incubation, apoptosis was analyzed using an Annexin V Apoptosis Detection kit (Biosea, Beijing, China) with a FACSCalibur flow cytometer (Becton Dickinson).
Laser scanning confocal microscopy The HeLa or PC-3 cells were attached to coverslips coated with fibronectin or nothing, fixed with freshly prepared 4% formaldehyde in PBS for 10 min at room temperature. Permeabilized with 0.25% Triton X-100, blocked at room temperature for1 h in PBS containing 10% normal goat serum. Then incubated at 4 1C overnight with anti-P-gp mAb, washed three times for 5 min with PBS, then incubated at room temperature with FITC-conjugated goat anti-mouse IgG for 40 min. Following incubation, coverslips were washed three times for 5 min with PBS, blocked with 5% bovine serum albumin, then incubated at 4 1C overnight with anti-LAPTM4B35 pAb, washed three times for 5 min with PBS, then incubated at room temperature with TRITC-conjugated goat anti-rabbit IgG for 40 min. Coverslips were then counterstained for 10 min with DAPI. The observation was made using a Leica TCS SP2 Laser Scanning Confocal Microscope (Leica Microsystems, Mannheim, Germany).
Statistical analysis
Statistical analysis was performed using Student's t-test. A P value o0.05 was considered statistically significant. All experiments were repeated at least twice.
